447 related articles for article (PubMed ID: 8797593)
1. MUC1-specific targeting immunotherapy with bispecific antibodies: inhibition of xenografted human bile duct carcinoma growth.
Katayose Y; Kudo T; Suzuki M; Shinoda M; Saijyo S; Sakurai N; Saeki H; Fukuhara K; Imai K; Matsuno S
Cancer Res; 1996 Sep; 56(18):4205-12. PubMed ID: 8797593
[TBL] [Abstract][Full Text] [Related]
2. Effective adoptive immunotherapy by T-LAK cells retargeted with bacterial superantigen-conjugated antibody to MUC1 in xenografted severe combined immunodeficient mice.
Shinoda M; Kudo T; Suzuki M; Katayose Y; Sakurai N; Saeki H; Kodama H; Fukuhara K; Imai K; Hinoda Y; Matsuno S
Cancer Res; 1998 Jul; 58(13):2838-43. PubMed ID: 9661899
[TBL] [Abstract][Full Text] [Related]
3. Specific and effective targeting cancer immunotherapy with a combination of three bispecific antibodies.
Kodama H; Suzuki M; Katayose Y; Shinoda M; Sakurai N; Takemura S; Yoshida H; Saeki H; Asano R; Ichiyama M; Imai K; Hinoda Y; Matsuno S; Kudo T
Immunol Lett; 2002 Apr; 81(2):99-106. PubMed ID: 11852114
[TBL] [Abstract][Full Text] [Related]
4. A mutated superantigen SEA D227A fusion diabody specific to MUC1 and CD3 in targeted cancer immunotherapy for bile duct carcinoma.
Takemura S; Kudo T; Asano R; Suzuki M; Tsumoto K; Sakurai N; Katayose Y; Kodama H; Yoshida H; Ebara S; Saeki H; Imai K; Matsuno S; Kumagai I
Cancer Immunol Immunother; 2002 Mar; 51(1):33-44. PubMed ID: 11845258
[TBL] [Abstract][Full Text] [Related]
5. Construction and in vivo evaluation of an anti-PSA x anti-CD3 bispecific antibody for the immunotherapy of prostate cancer.
Katzenwadel A; Schleer H; Gierschner D; Wetterauer U; Elsässer-Beile U
Anticancer Res; 2000; 20(3A):1551-5. PubMed ID: 10928069
[TBL] [Abstract][Full Text] [Related]
6. Humanization of the bispecific epidermal growth factor receptor x CD3 diabody and its efficacy as a potential clinical reagent.
Asano R; Sone Y; Makabe K; Tsumoto K; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
Clin Cancer Res; 2006 Jul; 12(13):4036-42. PubMed ID: 16818703
[TBL] [Abstract][Full Text] [Related]
7. Bispecific anti-CD22/anti-CD3-ricin A chain immunotoxin is cytotoxic to Daudi lymphoma cells but not T cells in vitro and shows both A-chain-mediated and LAK-T-mediated killing.
Shen GL; Li JL; Vitetta ES
J Immunol; 1994 Mar; 152(5):2368-76. PubMed ID: 8133047
[TBL] [Abstract][Full Text] [Related]
8. Mutated SEA-D227A-conjugated antibodies greatly enhance antitumor activity against MUC1-expressing bile duct carcinoma.
Kodama H; Suzuki M; Katayose Y; Shinoda M; Sakurai N; Takemura S; Yoshida H; Saeki H; Ichiyama M; Tsumoto K; Asano R; Kumagai I; Imai K; Hinoda Y; Matsuno S; Kudo T
Cancer Immunol Immunother; 2001 Dec; 50(10):539-48. PubMed ID: 11776376
[TBL] [Abstract][Full Text] [Related]
9. Combination of interleukin-2-stimulated lymphocytes and bispecific antibodies that efficiently lyse leukemic cells does not affect bone marrow CD34-positive stem cell function in vitro.
Kaneko T; Fukuda J; Teramura M; Fusauchi Y; Kakui Y; Okumura K; Mizoguchi H; Oshimi K
Bone Marrow Transplant; 1994 Aug; 14(2):213-7. PubMed ID: 7527685
[TBL] [Abstract][Full Text] [Related]
10. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model.
Senba T; Kuroki M; Arakawa F; Yamamoto T; Kuwahara M; Haruno M; Ikeda S; Matsuoka Y
Anticancer Res; 1998; 18(1A):17-24. PubMed ID: 9568050
[TBL] [Abstract][Full Text] [Related]
11. Antitumor effects of a bispecific antibody targeting CA19-9 antigen and CD16.
Garcia de Palazzo I; Holmes M; Gercel-Taylor C; Weiner LM
Cancer Res; 1992 Oct; 52(20):5713-9. PubMed ID: 1394194
[TBL] [Abstract][Full Text] [Related]
12. In vivo studies using bispecific antibodies (anti-CD3 x anti-idiotype) and CD28-induced costimulation in the BCL1 lymphoma.
Demanet C; Brissinck J; De Jonge J; Thielemans K
J Hematother; 1995 Oct; 4(5):363-8. PubMed ID: 8581370
[TBL] [Abstract][Full Text] [Related]
13. Specific targeting immunotherapy of cancer with bispecific antibodies.
Kudo T; Suzuki M; Katayose Y; Shinoda M; Sakurai N; Kodama H; Ichiyama M; Takemura S; Yoshida H; Saeki H; Saijyo S; Takahashi J; Tominaga T; Matsuno S
Tohoku J Exp Med; 1999 Aug; 188(4):275-88. PubMed ID: 10598685
[TBL] [Abstract][Full Text] [Related]
14. Diabody-based recombinant formats of humanized IgG-like bispecific antibody with effective retargeting of lymphocytes to tumor cells.
Asano R; Kawaguchi H; Watanabe Y; Nakanishi T; Umetsu M; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
J Immunother; 2008 Oct; 31(8):752-61. PubMed ID: 18779744
[TBL] [Abstract][Full Text] [Related]
15. Cytolysis of malignant glioma cells by lymphokine-activated killer cells combined with anti-CD3/antiglioma bifunctional antibody and tumor necrosis factor-alpha.
Yoshida J; Takaoka T; Mizuno M; Momota H; Okada H
J Surg Oncol; 1996 Jul; 62(3):177-82. PubMed ID: 8667624
[TBL] [Abstract][Full Text] [Related]
16. [Induction of cytotoxicity from human lymphocytes coated with bispecific antibody against human glioma cells].
Nitta T; Ishizawa A; Ito M; Sato K; Yagita H; Kumura K
No Shinkei Geka; 1990 Nov; 18(11):1001-6. PubMed ID: 2247192
[TBL] [Abstract][Full Text] [Related]
17. A highly effective and stable bispecific diabody for cancer immunotherapy: cure of xenografted tumors by bispecific diabody and T-LAK cells.
Hayashi H; Asano R; Tsumoto K; Katayose Y; Suzuki M; Unno M; Kodama H; Takemura S; Yoshida H; Makabe K; Imai K; Matsuno S; Kumagai I; Kudo T
Cancer Immunol Immunother; 2004 Jun; 53(6):497-509. PubMed ID: 14648071
[TBL] [Abstract][Full Text] [Related]
18. CD3-CD28 costimulation as a means to avoiding T cell preactivation in bispecific monoclonal antibody-based treatment of ovarian carcinoma.
Mazzoni A; Mezzanzanica D; Jung G; Wolf H; Colnaghi MI; Canevari S
Cancer Res; 1996 Dec; 56(23):5443-9. PubMed ID: 8968099
[TBL] [Abstract][Full Text] [Related]
19. Activation of resting T cells against the CA 72-4 tumor antigen with an anti-CD3/CA 72-4 bispecific antibody in combination with a costimulatory anti-CD28 antibody.
Hombach A; Mathas S; Jensen M; Tillmann T; Menges M; Diehl V; Kruis W; Pohl C
Anticancer Res; 1997; 17(3C):2025-32. PubMed ID: 9216660
[TBL] [Abstract][Full Text] [Related]
20. Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3 x anti-CEA bispecific diabodies and B7 x anti-CEA bispecific fusion proteins.
Holliger P; Manzke O; Span M; Hawkins R; Fleischmann B; Qinghua L; Wolf J; Diehl V; Cochet O; Winter G; Bohlen H
Cancer Res; 1999 Jun; 59(12):2909-16. PubMed ID: 10383154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]